Advisors Asset Management Inc. Raises Position in Alexion Pharmaceuticals, Inc. (ALXN)

Advisors Asset Management Inc. increased its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 24.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,428 shares of the biopharmaceutical company’s stock after purchasing an additional 3,572 shares during the period. Advisors Asset Management Inc.’s holdings in Alexion Pharmaceuticals were worth $2,288,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ALXN. Iridian Asset Management LLC CT raised its position in shares of Alexion Pharmaceuticals by 14,950.7% during the 2nd quarter. Iridian Asset Management LLC CT now owns 1,496,192 shares of the biopharmaceutical company’s stock worth $185,752,000 after purchasing an additional 1,486,251 shares during the last quarter. Sound Shore Management Inc. CT acquired a new position in Alexion Pharmaceuticals in the 2nd quarter valued at $134,590,000. Swedbank acquired a new position in Alexion Pharmaceuticals in the 2nd quarter valued at $101,913,000. Putnam Investments LLC raised its holdings in Alexion Pharmaceuticals by 58.4% in the 2nd quarter. Putnam Investments LLC now owns 1,160,859 shares of the biopharmaceutical company’s stock valued at $144,120,000 after acquiring an additional 428,033 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its holdings in Alexion Pharmaceuticals by 415.1% in the 2nd quarter. Point72 Asset Management L.P. now owns 437,800 shares of the biopharmaceutical company’s stock valued at $54,353,000 after acquiring an additional 352,800 shares during the last quarter. Hedge funds and other institutional investors own 92.93% of the company’s stock.

Several research analysts have weighed in on the company. ValuEngine upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, September 24th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $152.00 price target for the company in a report on Monday, July 16th. BidaskClub upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 10th. Leerink Swann set a $181.00 price target on Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $123.00 price target on shares of Alexion Pharmaceuticals in a report on Friday, July 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $161.24.



ALXN stock opened at $116.27 on Friday. The firm has a market cap of $26.14 billion, a PE ratio of 22.53, a PEG ratio of 1.07 and a beta of 0.79. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.16 and a quick ratio of 2.27. Alexion Pharmaceuticals, Inc. has a 52 week low of $102.10 and a 52 week high of $140.77.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Wednesday, October 24th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.74 by $0.28. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. Alexion Pharmaceuticals had a return on equity of 16.60% and a net margin of 3.90%. The business’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.44 EPS. On average, analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.45 earnings per share for the current fiscal year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Featured Article: How to Calculate Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply